Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keith T Flaherty

Showing results (1-10 of 418) with videos related to

Pageof 42
Sort By:
Clinical Advances in Hematology & Oncology : H&O|April 9, 2016
New drugs in development for melanomaKeith T Flaherty
Cancer|November 6, 2009
Where does the combination of sorafenib and interferon in renal cell carcinoma stand?Keith T Flaherty
Pigment Cell & Melanoma Research|July 21, 2012
Throwing the kitchen sink at melanoma drug developmentKeith T Flaherty
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2006
Chemotherapy and targeted therapy combinations in advanced melanomaKeith T Flaherty
Cancer Biology & Therapy|March 26, 2015
When are signal transduction targeted therapies acting as immunotherapy?Keith T Flaherty
Expert Review of Anticancer Therapy|May 12, 2007
Sorafenib: delivering a targeted drug to the right targetsKeith T Flaherty
Cancer Journal (Sudbury, Mass.)|December 14, 2011
BRAF inhibitors and melanomaKeith T Flaherty
Clinical & Experimental Metastasis|June 5, 2012
Dividing and conquering: controlling advanced melanoma by targeting oncogene-defined subsetsKeith T Flaherty
Clinical Advances in Hematology & Oncology : H&O|September 17, 2005
VEGFR-targeted therapyKeith T Flaherty
Pigment Cell & Melanoma Research|February 14, 2015
Effectively targeting CRAF: rational serendipity targeting SRC?Keith T Flaherty
Pageof 42

Showing results (1-10 of 418) with videos related to

Sort By:
Pageof 42
Clinical Advances in Hematology & Oncology : H&O|April 9, 2016
New drugs in development for melanomaKeith T Flaherty
Cancer|November 6, 2009
Where does the combination of sorafenib and interferon in renal cell carcinoma stand?Keith T Flaherty
Pigment Cell & Melanoma Research|July 21, 2012
Throwing the kitchen sink at melanoma drug developmentKeith T Flaherty
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2006
Chemotherapy and targeted therapy combinations in advanced melanomaKeith T Flaherty
Cancer Biology & Therapy|March 26, 2015
When are signal transduction targeted therapies acting as immunotherapy?Keith T Flaherty
Expert Review of Anticancer Therapy|May 12, 2007
Sorafenib: delivering a targeted drug to the right targetsKeith T Flaherty
Cancer Journal (Sudbury, Mass.)|December 14, 2011
BRAF inhibitors and melanomaKeith T Flaherty
Clinical & Experimental Metastasis|June 5, 2012
Dividing and conquering: controlling advanced melanoma by targeting oncogene-defined subsetsKeith T Flaherty
Clinical Advances in Hematology & Oncology : H&O|September 17, 2005
VEGFR-targeted therapyKeith T Flaherty
Pigment Cell & Melanoma Research|February 14, 2015
Effectively targeting CRAF: rational serendipity targeting SRC?Keith T Flaherty
Pageof 42